Suzanne E. Patton

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 519 citations · Full text

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 280 citations · Full text

Phase I/II Study of 19-<i>nor</i>-1α-25-Dihydroxyvitamin D2 (Paricalcitol) in Advanced, Androgen-Insensitive Prostate Cancer

Gary G. Schwartz, M. Craig Hall, Diana Stindt et al. · Clinical Cancer Research · 2005 · 77 citations

Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.

Suzanne E. Patton, Michael L. Martin, Lori Nelsen et al. · PubMed · 1998 · 58 citations

Ras-mitogen-activated Protein, Ras Gene, Cancer Biology +16

Characterization of delayed neurotoxicity in the mouse following chronic oral administration of tri-o-cresyl phosphate

Daniel M. Lapadula, Suzanne E. Patton, Gerald A. Campbell et al. · Toxicology and Applied Pharmacology · 1985 · 44 citations

Medicine, Delayed Neurotoxicity, Toxicology +8